Preferred Label : efgartigimod alfa;
UNII : 961YV2O515;
Origin ID : C000718373;
UMLS CUI : C5139924;
ATC code(s)
- Currated CISMeF NLP mapping
- MeSH term(s) associated for indexing
- Record concept(s)
- Semantic type(s)
- UMLS correspondences (same concept)
- Validated automatic mappings to BTNT
https://www.has-sante.fr/jcms/p_3516768/fr/vyvgart-efgartigimod-alfa-myasthenie-auto-immune-generalisee
2024
false
false
false
France
evaluation of the transparency committee
Diffuse
myasthenia gravis, generalized
efgartigimod alfa
efgartigimod alfa
Pervasive
myasthenia gravis
Efgartigimod Alfa
Myasthenia Gravis
Vyvgart
---
https://ansm.sante.fr/tableau-acces-derogatoire/vyvgart
2024
false
false
false
France
French
efgartigimod alfa
infusions, intravenous
myasthenia gravis, generalized
Acetylcholine receptor antibody (substance)
Anti-acetylcholine receptor antibody positivity
efgartigimod alfa
generalised myasthenia gravis with anti-acetylcholine receptor antibody
drug information
---
https://www.has-sante.fr/jcms/p_3536075/fr/vyvgart-efgartigimod-alfa-myasthenie-auto-immune-generalisee
2024
false
false
false
France
generalised myasthenia gravis with anti-acetylcholine receptor antibody
myasthenia gravis
myasthenia gravis, generalized
insurance, health, reimbursement
treatment outcome
adult
efgartigimod alfa
evaluation of the transparency committee
efgartigimod alfa
---
https://www.has-sante.fr/jcms/p_3455583/fr/vyvgart-efgartigimod-alfa-myasthenie-auto-immune-generalisee
2023
false
false
false
France
French
treatment outcome
efgartigimod alfa
evaluation of the transparency committee
myasthenia gravis, generalized
efgartigimod alfa
---
https://www.ema.europa.eu/en/medicines/human/EPAR/vyvgart
2022
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
Vyvgart
efgartigimod alfa
efgartigimod alfa
orphan drug production
drug approval
europe
myasthenia gravis, generalized
myasthenia gravis
adult
infusions, intravenous
fc receptor, neonatal
product surveillance, postmarketing
Anti-acetylcholine receptor antibody positivity
drug interactions
pregnancy
breast feeding
efgartigimod alfa
drug evaluation, preclinical
---
https://www.has-sante.fr/jcms/p_3359123/fr/vyvgart-efgartigimod-alfa-myasthenie-auto-immune-generalisee
https://www.has-sante.fr/jcms/p_3359140/fr/decision-n2022-0279/dc/sem-du-21-juillet-2022-du-college-de-la-haute-autorite-de-sante-portant-autorisation-d-acces-precoce-de-la-specialite-vyvgart
2022
false
false
false
France
insurance, health, reimbursement
treatment outcome
guidelines for drug use
drug therapy, combination
adult
Anti-acetylcholine receptor antibody positivity
infusions, intravenous
antibodies, monoclonal, humanized
efgartigimod alfa
evaluation of the transparency committee
myasthenia gravis
Vyvgart
efgartigimod alfa
myasthenia gravis, generalized
---
https://www.has-sante.fr/jcms/p_3402357/fr/vyvgart-efgartigimod-alfa-myasthenie
2022
false
false
false
France
treatment outcome
insurance, health, reimbursement
efgartigimod alfa
orphan drug production
infusions, intravenous
drug therapy, combination
myasthenia gravis, generalized
myasthenia gravis
Acetylcholine receptor antibody (substance)
evaluation of the transparency committee
myasthenia gravis
efgartigimod alfa
Vyvgart
---
